Liver Protection by Bis(Maltolato)Zinc(II) Complex

DOI Web Site Web Site PubMed 4 Citations 63 References
  • KAWASE Masaya
    Graduate School of Pharmaceutical Sciences, Osaka University
  • KAGAYA Noritaka
    Graduate School of Pharmaceutical Sciences, Osaka University
  • AKAMATSU Soh-ichiro
    Graduate School of Pharmaceutical Sciences, Osaka University
  • KAMIYOSHI Akiko
    Division of Laboratory Animal Research, Research Center for Human and Environmental Science, Shinshu University
  • MUTO Shin-ichi
    Toxicology Research Laboratory, R&D, Kissei Pharmaceutical Co. Ltd.
  • TAGAWA Yoh-ichi
    Division of Laboratory Animal Research, Research Center for Human and Environmental Science, Shinshu University
  • YAGI Kiyohito
    Graduate School of Pharmaceutical Sciences, Osaka University

Bibliographic Information

Other Title
  • Liver Protection by Bis Maltolato Zinc 2 Complex

Search this article

Abstract

The aim of this study was to perform screening of a novel drug for treating liver injury. Bis(maltolato)zinc(II) complex [Zn(Mal)2], which was previously reported to possess insulinomimetic activity, was found to have potency against experimentally induced liver injury both in vitro and in vivo. Cultured rat hepatocytes were treated with bromobenzene for 24 h to induce cellular injury. Zn(Mal)2 of various concentrations was added along with bromobenzene in order to evaluate the hepatoprotective activity of Zn(Mal)2 in vitro. The number of viable hepatocytes decreased by 42% in the culture with bromobenzene. However, hepatocyte viability was maintained when Zn(Mal)2 was added to the bromobenzene culture. The hepatoprotective activity of Zn(Mal)2 in vivo was investigated using a concanavalin A-induced liver injury model in BALB/c mice. Changes in serum aminotransferase activities and the secretion of several cytokines were measured. The hepatoprotective effect of Zn(Mal)2 was also demonstrated in vivo by the suppression of serum aspartate aminotransferase and alanine aminotransferase elevation. No significant changes in serum cytokines associated with the induction of hepatic damage were observed in the concanavalin A-induced injury model. However, examination of concanavalin A-treated mouse splenocytes revealed a dose-dependent suppression of cytokine secretions by Zn(Mal)2. Zn(Mal)2 possessed hepatoprotective activity and might exert its effect by a number of mechanisms.<br>

Journal

  • Experimental Animals

    Experimental Animals 53 (1), 1-9, 2004

    Japanese Association for Laboratory Animal Science

Citations (4)*help

See more

References(63)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top